



<p>UTILITY PATENT APPLICATION TRANSMITTAL <i>Submit an original and a duplicate for fee processing Only for new nonprovisional applications under 37 CFR §1.53(b))</i></p>		Attorney Docket No.	213187
		First Inventor	KOVESDI, Imre
		Title	ADENOVECTOR PHARMACEUTICAL COMPOSITION
		Express Mail No.	EF125999585US
APPLICATION ELEMENTS		ADDRESS TO:	Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p>1. <input checked="" type="checkbox"/> Utility Patent Application Transmittal Form</p> <p>2. <input type="checkbox"/> Applicant claims small entity status. <i>See 37 CFR 1.27.</i></p> <p>3. <input checked="" type="checkbox"/> Specification (including claims and abstract) [Total Pages 41]</p> <p>4. <input checked="" type="checkbox"/> Drawings [Total Sheets 4]</p> <p>5. <input checked="" type="checkbox"/> Combined Declaration and Power of Attorney [Total Pages 4]</p> <p>a. <input type="checkbox"/> Unexecuted</p> <p>b. <input checked="" type="checkbox"/> Copy from prior application [Note Box 6 below]</p> <p>i. <input type="checkbox"/> <u>Deletion of Inventor(s)</u> Signed statement attached deleting inventor(s) named in the prior application</p> <p>6. <input checked="" type="checkbox"/> Incorporation by Reference: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b is considered as part of the disclosure of the accompanying application and is hereby incorporated by reference.</p> <p>7. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76</p> <p>8. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)</p> <p>9. Nucleotide and/or Amino Acid Sequence Submission</p> <p>a. <input checked="" type="checkbox"/> Computer Readable Form (CRF)</p> <p>b. Specification Sequence Listing on:</p> <p>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</p> <p>ii. <input checked="" type="checkbox"/> Paper Copy</p> <p>c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</p>		ACCOMPANYING APPLICATION PARTS <p>10. <input type="checkbox"/> Applicant requests early publication. (include publication fee under 37 CFR 1.18(d))</p> <p>11. <input type="checkbox"/> Assignment Papers (cover sheet and document(s))</p> <p>12. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an Assignee)</p> <p>13. <input type="checkbox"/> Power of Attorney</p> <p>14. <input type="checkbox"/> English Translation Document (if applicable)</p> <p>15. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)</p> <p><input checked="" type="checkbox"/> Form PTO-1449</p> <p><input checked="" type="checkbox"/> Copies of Listed Documents</p> <p>16. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>17. <input checked="" type="checkbox"/> Return Receipt Postcard (Should be specifically itemized)</p> <p>18. <input type="checkbox"/> Certified Copy of Priority Document(s)</p> <p>19. <input type="checkbox"/> Request & Certification Under 35 USC 122(b)(2)(B)(i) (Form PTO/SB/35 or its equivalent attached)</p> <p>20. <input checked="" type="checkbox"/> Other: Amendments to Specification and Claims Made via Preliminary Amendment. Pending Claims After Entry of Preliminary Amendment. Submission of Formal Drawings.</p>	
<p>21. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information in (a) and (b) below:</p> <p>(a) <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part of prior Application No. 08/258,416, filed on June 10, 1994, which is incorporated by reference. Prior application information: Examiner: Scott D. Priebe; Group Art Unit: 1632.</p> <p>(b) Preliminary Amendment: Benefit of earlier filing date - 35 USC 120. The Commissioner is requested to amend the specification by inserting the following sentence before the first line: "This is a <input type="checkbox"/> continuation <input type="checkbox"/> divisional <input type="checkbox"/> continuation-in-part (CIP) of <input type="checkbox"/> Application No. , filed on , which is incorporated by reference." <input type="checkbox"/> International Application No. , filed on , which designates the U.S., and which is incorporated by reference."</p>			

UTILITY PATENT APPLICATION TRANSMITTAL			Attorney Docket No.	213187	
APPLICATION FEES					
BASIC FEE				\$ 710.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	20 - 20 =	0	x \$18.00	\$ 0.00	
Independent Claims	1 - 3 =	0	x \$80.00	\$ 0.00	
<input type="checkbox"/> Multiple Dependent Claim if applicable				+\$270.00	
				\$ 0.00	
				Total of above calculations =	\$ 710.00
				Reduction by 50% for filing by small entity =	(\$ 0.00)
<input type="checkbox"/> Assignment fee if applicable				+ \$40.00	\$ 0.00
<input type="checkbox"/> Early publication fee if applicable				+ \$300.00	\$ 0.00
				TOTAL =	\$ 710.00

22. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 12-1216 in the amount of \$ 710.00.	
23. <input type="checkbox"/> A check in the amount of \$ _____ is enclosed.	
24. The Commissioner is hereby authorized to credit overpayments or charge any additional fees of the following types to Deposit Account No. 12-1216:	
a. <input checked="" type="checkbox"/> Fees required under 37 CFR 1.16.	
b. <input checked="" type="checkbox"/> Fees required under 37 CFR 1.17.	
25. <input checked="" type="checkbox"/> The Commissioner is hereby generally authorized under 37 CFR 1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 CFR 1.53 requiring an extension of time as incorporating a request therefor, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 12-1216 for any fee that may be due in connection with such a request for an extension of time.	
26. CORRESPONDENCE ADDRESS	
<input checked="" type="checkbox"/> Customer Number: 23460  23460 <small>PATENT TRADEMARK OFFICE</small>	<input type="checkbox"/> , Reg. No. Leydig, Voit & Mayer, Ltd. Two Prudential Plaza, Suite 4900 180 North Stetson Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)
Name	John Kilyk, Jr., Registration No. 30,763
Signature	
Date	August 21, 2001

Certificate of Mailing Under 37 CFR 1.10

I hereby certify that this Utility Patent Application Transmittal and all accompanying documents are being deposited with the United States Postal Service "Express Mail Post Office To Addressee" Service under 37 CFR 1.10 on the date indicated below and is addressed to: Assistant Commissioner of Patents, Box Patent Application, Washington, D.C. 20231.

Peter Phillips		August 21, 2001
Name of Person Signing	Signature	Date

Utility (Rev. 11/13/2000)

PATENT

Attorney Docket No. 213187

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kovesdi et al.

Group Art Unit: Unassigned

Continuation of Application No. 08/258,416
filed June 10, 1994

Examiner: Unassigned

Filing Date: August 21, 2001

For: ADENOVECTOR PHARMACEUTICAL
COMPOSITION


**SUBMISSION OF NUCLEOTIDE/AMINO ACID SEQUENCE DISCLOSURES AND
STATEMENT UNDER 37 C.F.R. §§ 1.821-1.825**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In accordance with the requirements of 37 C.F.R. §§ 1.821-1.825, a sequence listing forms part of the disclosure of the instant patent application. A paper copy of a sequence listing has been inserted immediately prior to the claims in the patent application. A computer readable copy on a computer diskette, prepared by applicants with the use of the PatentIn v.1.0 software, is enclosed herewith. The undersigned hereby verifies that the contents of the paper and the computer readable copies are the same.

Respectfully submitted,


John Kilyk, Jr., Registration No. 30,763
One of the Attorneys for Applicants
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: August 21, 2001

PATENT
Attorney Docket No. 213187

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kovesdi et al.

Group Art Unit: Unassigned

Continuation of Application No. 08/258,416
filed June 10, 1994

Examiner: Unassigned

Filing Date: August 21, 2001

For: **ADENOVECTOR PHARMACEUTICAL
COMPOSITION**

SUBMISSION OF FORMAL DRAWINGS

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicants enclose herewith three (3) sheets of formal drawings and request that the same be made of record in the above-identified patent application.

The Assistant Commissioner is hereby authorized to charge any fees that may be required to Account No. 12-1216. A duplicate copy of this communication is enclosed for that purpose.

Respectfully submitted,


John Klyk, Jr., Reg. No. 30763
One of the Attorneys for Applicants
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: August 21, 2001